Journal of Pediatric Urology
Volume 5, Issue 5 , Page 344 , October 2009

Commentary to “Controversies in the management of vesicoureteral reflux – The rationale for the RIVUR study”

Received 7 April 2009 ,Accepted 17 April 2009.

References 

  1. Koyle MA, Caldamone AA. Part 4: Considerations regarding the medical management of VUR: what have we really learned?. Curr Med Res Opin. 2007;23:S21–S25
  2. Olbing H, Smellie JM, Jodal U, Lax H. New renal scars in children with severe VUR: a 10-year study of randomized treatment. Pediatr Nephrol. 2003;18:1128–1131
  3. Stenberg A, Läckgren G. Treatment of vesicoureteral reflux in children using stabilized non-animal hyaluronic acid/dextranomer gel (NASHA/DX: a long-term observational study). J Pediatr Urol. 2007;3:80–85
  4. Puri P, Mohanan N, Menezes M, Colhoun E. Endoscopic treatment of moderate and high grade vesicoureteral reflux in infants using dextranomer /hyaluronic acid. J Urol. 2007;
  5. Wadie GM, Tirabassi MV, Courtney RA, Moriarty KP. The deflux procedure reduces the incidence of urinary tract infections in patients with vesicoureteral reflux. J Laparoendosc Adv Surg Tech A. 2007;17:353–359
  6. Wheeler DM, Vimalachandra D, Hodson EM, Roy LP, Smith GH, Craig JC. Interventions for primary vesicoureteric reflux. Cochrane Database Syst Rev. 2004;(3):CD001532

PII: S1477-5131(09)00314-3

doi: 10.1016/j.jpurol.2009.04.011

Journal of Pediatric Urology
Volume 5, Issue 5 , Page 344 , October 2009

Article Tools